Guy Chouinard

Summary

Publications

  1. pmc Interrelations between psychiatric symptoms and drug-induced movement disorder
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montreal, Que, Canada
    J Psychiatry Neurosci 31:177-80. 2006
  2. pmc The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montreal, Que, Canada
    J Psychiatry Neurosci 31:168-76. 2006
  3. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:703-14. 2005
  4. ncbi request reprint Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC
    Can J Clin Pharmacol 13:e69-74. 2006
  5. ncbi request reprint Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use
    Emmanuelle Levy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 49:398-402. 2004
  6. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:541-7. 2005
  7. ncbi request reprint Topiramate-induced weight loss in schizophrenia: a retrospective case series study
    Emmanuel Lévy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    Can J Clin Pharmacol 14:e234-9. 2007
  8. ncbi request reprint Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound
    Guy Chouinard
    Centre de Recherche Fernand Seguin, Psychopharmacologie, Departement de Psychiatrie, Universite de Montreal, Hôpital Louis Lafontaine, Montreal, Quebec, Canada
    J Clin Psychiatry 65:7-12. 2004
  9. ncbi request reprint A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC, Canada
    Eur Neuropsychopharmacol 14:87-92. 2004
  10. ncbi request reprint New nomenclature for drug-induced movement disorders including tardive dyskinesia
    Guy Chouinard
    Fernand Seguin Research Center, Louis H Lafontaine Hospital, University of Montreal and the Allan Memorial Institute, McGill University Health Center, Montreal, Quebec, Canada
    J Clin Psychiatry 65:9-15. 2004

Collaborators

Detail Information

Publications31

  1. pmc Interrelations between psychiatric symptoms and drug-induced movement disorder
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montreal, Que, Canada
    J Psychiatry Neurosci 31:177-80. 2006
    ....
  2. pmc The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montreal, Que, Canada
    J Psychiatry Neurosci 31:168-76. 2006
    ....
  3. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:703-14. 2005
    ..We sought to explore the incidence and management of TD in the era of atypical antipsychotics because it remains an important iatrogenic adverse effect...
  4. ncbi request reprint Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC
    Can J Clin Pharmacol 13:e69-74. 2006
    ..To describe tardive rebound anxiety phenomena (panic, anxiety and insomnia) following abrupt paroxetine discontinuation...
  5. ncbi request reprint Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use
    Emmanuelle Levy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 49:398-402. 2004
    ..This study examines the links among diabetes, tardive dyskinesia (TD), and other extrapyramidal symptoms (EPS) in schizophrenia outpatients treated with typical and atypical antipsychotics...
  6. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:541-7. 2005
    ..Several mechanisms may exist for this phenomenon. Mechanisms for the lower incidence of TD with atypical antipsychotics also remain to be fully understood. We undertook to explore and better understand these mechanisms...
  7. ncbi request reprint Topiramate-induced weight loss in schizophrenia: a retrospective case series study
    Emmanuel Lévy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    Can J Clin Pharmacol 14:e234-9. 2007
    ..Atypical antipsychotics have been associated with weight gain. This study examines the efficacy of adjunctive topiramate in patients with schizophrenia and schizoaffective disorder with antipsychotic-induced weight gain...
  8. ncbi request reprint Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound
    Guy Chouinard
    Centre de Recherche Fernand Seguin, Psychopharmacologie, Departement de Psychiatrie, Universite de Montreal, Hôpital Louis Lafontaine, Montreal, Quebec, Canada
    J Clin Psychiatry 65:7-12. 2004
    ..Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome...
  9. ncbi request reprint A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC, Canada
    Eur Neuropsychopharmacol 14:87-92. 2004
    ..Besides positive and negative symptom control, they may improve cognition. Due to their limited availability as oral agents only, benefits are limited by noncompliance...
  10. ncbi request reprint New nomenclature for drug-induced movement disorders including tardive dyskinesia
    Guy Chouinard
    Fernand Seguin Research Center, Louis H Lafontaine Hospital, University of Montreal and the Allan Memorial Institute, McGill University Health Center, Montreal, Quebec, Canada
    J Clin Psychiatry 65:9-15. 2004
    ..This new classification system will provide clinicians and researchers across specialties a more precise language, which will hopefully improve the diagnosis of and research criteria for D-IMD...
  11. ncbi request reprint Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, Montreal, QC, Canada, H3A 1A1
    Schizophr Res 76:247-65. 2005
    ..ESRS specificity was investigated through two different approaches, path analyses and ANCOVA PANSS factors changes, which found that ESRS measurement of drug-induced EPS is valid and discriminative from psychiatric symptoms...
  12. ncbi request reprint Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia
    Gerald Pfeffer
    Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Int Clin Psychopharmacol 20:179-81. 2005
    ..Gabapentin may be effective by mechanisms similar to its action in restless legs syndrome and Parkinsonism, and/or via the GABA neurotransmitter system...
  13. ncbi request reprint Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder
    Howard C Margolese
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, Quebec, Canada
    J Clin Psychopharmacol 22:347-52. 2002
    ..Seeman and Tallerico3 have proposed pharmacologic explanations for quetiapine and clozapine drug-induced rebound phenomena...
  14. ncbi request reprint Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial
    Yves Dion
    Allan Memorial Institute, Royal Victoria Hospital and Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    J Clin Psychopharmacol 22:31-9. 2002
    ..Risperidone did not increase obsessive-compulsive symptoms. Fatigue and somnolence were the most common adverse events associated with risperidone...
  15. ncbi request reprint Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
    Arch Gen Psychiatry 60:82-91. 2003
    ..Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients...
  16. ncbi request reprint The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
    ..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
  17. ncbi request reprint Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic-induced parkinsonism
    Jean Pierre Schuster
    Psychiatry Clin Neurosci 61:206. 2007
  18. doi request reprint Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes
    Guy Chouinard
    Psychother Psychosom 77:69-77. 2008
  19. ncbi request reprint Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, NJ 08560, USA
    Schizophr Res 77:119-28. 2005
    ....
  20. ncbi request reprint Seizures, coma, and coagulopathy following olanzapine overdose
    Nadeem H Bhanji
    Can J Psychiatry 50:126-7. 2005
  21. ncbi request reprint Clozapine for first-episode schizophrenia
    Theodore T Kolivakis
    Am J Psychiatry 159:317. 2002
  22. ncbi request reprint Using the rating scale for psychotic symptoms to characterize delusions expressed in a schizophrenia patient with "Internet psychosis"
    Howard C Margolese
    Can J Psychiatry 47:485. 2002
  23. ncbi request reprint Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia
    Emmanuelle Levy
    J Clin Psychiatry 63:1045. 2002
  24. ncbi request reprint Hypomania induced by adjunctive lamotrigine
    Howard C Margolese
    Am J Psychiatry 160:183-4. 2003
  25. ncbi request reprint Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia
    Karin Jablonowski
    Can J Psychiatry 47:975-6. 2002
  26. ncbi request reprint Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine
    Emmanuelle Levy
    Can J Psychiatry 48:709-10. 2003
  27. ncbi request reprint Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment
    Padraig Wright
    Clinical Neuroscience, Lilly Research Centre, Eli Lilly and Company, Surrey, UK
    Can J Psychiatry 48:716-21. 2003
    ..To determine the antipsychotic efficacy and extrapyramidal safety of intramuscular (i.m.) olanzapine and i.m. haloperidol during the first 24 hours of treatment of acute schizophrenia...
  28. ncbi request reprint Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence
    Theodore T Kolivakis
    Can J Psychiatry 49:280. 2004
  29. ncbi request reprint ECT in delusional depression with multiple sclerosis
    Emmanuelle Corruble
    Am J Psychiatry 161:1715. 2004
  30. ncbi request reprint Risperidone-induced morning pseudoneutropenia
    David Esposito
    Am J Psychiatry 162:397. 2005
  31. doi request reprint Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype
    Fleur Breil
    Int J Neuropsychopharmacol 11:727-8. 2008